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We analyzed the genome of a rhabdoid glioblastoma (R-GBM) tumor, a very rare variant of GBM. A surgical
specimen of R-GBM from a 20-year-old woman was analyzed using whole exome sequencing (WES), whole
transcriptome sequencing (WTS), single nucleotide polymorphism array, and array comparative genomic
hybridization. The status of gene expression in R-GBM tissue was compared with that of normal brain tissue
and conventional GBM tumor tissue. We identified 23 somatic non-synonymous small nucleotide variants with
WES. We identified the BRAF V600E mutation and possible functional changes in the mutated genes, ISL1 and
NDRG2. Copy number alteration analysis revealed gains of chromosomes 3, 7, and 9. We found loss of
heterozygosity and focal homozygous deletion on 9q21, which includes CDKN2A and CDKN2B. In addition, WTS
revealed that CDK6, MET, EZH2, EGFR, and NOTCH1, which are located on chromosomes 7 and 9, were over-
expressed, whereas CDKN2A/2B were minimally expressed. Fusion gene analysis showed 14 candidate genes
that may be functionally involved in R-GBM, including TWIST2, and UPK3BL. The BRAF V600E mutation, CDKN2A/
2B deletion, and EGFR/MET copy number gain were observed. These simultaneous alterations are very rarely
found in GBM. Moreover, the NDRG2 mutation was first identified in this study as it has never been reported in
GBM. We observed a unique genomic signature in R-GBM compared to conventional GBM, which may provide
insight regarding R-GBM as a distinct disease entity among the larger group of GBMs.
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Rhabdoid glioblastoma (R-GBM) is a very rare disease with few cases
reported [1–8]. R-GBM is characterized by tumor cells that resemble
rhabdomyoblasts [2], which robustly express vimentin, epithelial
membrane antigen (EMA), and SMARCB1 (INI-1), but only faintly
express glial fibrillary acidic protein (GFAP) [5,7,9,10]. Clinically,
R-GBMs can occur at any age but most commonly occur in teenagers
younger than 20 years old [1,2,5].
Chromosome 22, which is frequently lost in atypical teratoid
rhabdoid tumors (ATRT), is often deleted in these tumors [3,8],
although this finding is inconsistent [1]. In one case, copy number
gains were noted for chromosomes 3, 7, 9, 12, 17q, and 21q [1] in
R-GBM. Also, in a case series, copy number gain or amplification of
EGFR on chromosome 7 was noted [9]. Regarding genetic changes
prevalent in brain tumors, CDKN2A hemizygous deletion was
reported in one case [2]. Otherwise, BRAF mutations were absent in
two cases that were examined [11], and SMARCB1 (INI-1) [12,13],
which is important in ATRT, was not mutated in R-GBM [2].
Presently, R-GBM is not recognized as a distinct disease entity by
the World Health Organization [14] classification system because
accumulated information on this rare variety is still rudimentary. To
our knowledge, no study has evaluated the genome-wide profile of
this disease except for one case that was evaluated using array
comparative genomic hybridization (CGH) [1]. To determine
whether R-GBM should be recognized as a disease that is distinct
from conventional glioblastoma (GBM) or other tumors with similar
characteristics such as ATRT, comprehensive genomic data will be
fundamental for diagnostic, prognostic, and therapeutic decisions.
A 20-year-old female presented with a rim-enhanced tumor that
was pathologically proven to be an R-GBM. She underwent twoFigure 1. Pathology of rhabdoid glioblastoma. (A) A representative
located pleomorphic nuclei and eosinophilic globular cytoplasm (H&E,
but not all, tumor cells (GFAP immunostaining, original magnificatio
pattern in almost all tumor cells (EMA immunohistochemistry, origin
positive in the nuclei of the tumor cells (cyclin D1 immunohistochemextensive surgeries and concurrent chemoradiotherapy combined
with oral temozolomide treatment. She was free of disease for 25
months after the treatment. Using next generation sequencing
techniques, we studied this tumor to obtain novel insight into
identifying distinctive genetic changes in an R-GBM compared to
conventional GBM as well as normal brain tissue. We performed
whole exome sequencing (WES), whole transcriptome sequencing
(WTS), single nucleotide polymorphism (SNP) array, and
array-CGH. The aims of this study were to investigate the genomic
profile of R-GBM and to explore whether R-GBM had a distinct
genomic signature that could be used as a therapeutic target.
Materials and Methods
Study Patient
A 20-year-old female patient was seen in an outpatient clinic at Seoul
National University Hospital because of headache, nausea, and
vomiting in April 2011. Brain magnetic resonance imaging showed a
5-cm sized, well-enhanced mass in the right temporal lobe. The mass
also showed diffusion restriction with increased perfusion at the
peripheral enhanced portion. She underwent a craniotomy for tumor
removal in May 2011. The molecular genetic characteristics of the
surgical specimen were evaluated as follows. Immunohistochemical
staining revealed focal expression of GFAP and strong expression of
EMA and INI-1 (Figure 1). Fluorescence in situ hybridization (FISH)
showed no EGFR amplification and no deletion of chromosomes 1p,
9p21, or 19q. In addition, methylation-specific PCR showed
hypermethylation of the MGMT promoter, and the MIB-1 labeling
index was measured as 36.5% with an Aperio Spectrum plus
image analyzer. The study patient received adjuvant concurrentH&E picture shows non-cohesive rhabdoid cells with eccentrically
original magnification ×200). (B) GFAP is robustly positive in some,
n ×200). (C) EMA is strongly positive in a cytoplasmic membrane
al magnification ×200). (D) Cyclin D1 (CCND1) staining is strongly
istry, original magnification ×200).
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However, the tumor recurred on the ipsilateral side of the frontal lobe,
and she underwent a second operation to remove the recurrent tumor.
The final pathology confirmed that, as with the initial mass, the
recurrent tumor was an R-GBM. The recurrent tumor had a MIB-1
labeling index of 37.5%. She has been free from disease for 25 months
as of December 2013. The study protocol was reviewed and approved
by the institutional review board of the Seoul National University
Hospital, and informed consent was obtained from the study patient.
The recommendations of the Declaration of Helsinki for biomedical
research involving human subjects were followed.
DNA and RNA Preparation
Fresh frozen tumor tissue and 5 ml peripheral blood were obtained
at the time of the first surgery. The DNeasy® Blood & Tissue Kit
(Qiagen, Hilden, Germany) was used to extract genomic DNA and
tumor DNA, according to the manufacturer’s recommendations.
Extracted DNA was quantified using a NanoDrop ND-1000
spectrophotometer (NanoDrop Technologies, Wilmington, DE).
RNA was extracted from the tumor tissue using TRIzol (Invitrogen,
Grand Island, NY) and eluted in RNAse-free water. RNA quantity
and quality were assessed using an Agilent 2100 Bioanalyzer (Agilent
Technologies Inc., Santa Clara, CA).
Whole Exome Sequencing
We used the Agilent SureSelect50-Mb ExomeCapture Kit for exon
target enrichment (Agilent Technologies Inc.). Sequencing was
performed using the Illumina HiSeq2000 (Illumina Inc., San
Diego, CA) with 100-bp paired-end reads. Using UCSC hg19 as a
reference genome, mapping and pairing were performed with the
Burrows-Wheeler Aligner (BWA) algorithm [15]. Local realignment
was performed using Genome Analysis ToolKit (GATK) [16], and
duplication removal was conducted using Picard.
Somatic calling of somatic single nucleotide variants (SNVs) and
indels is described in Supplement 1. Using SnpEff [17], we
selected variations that were non-synonymous and rare in the
general population (defined as b1% in the 1000 genome project
(http://www.1000genomes.org/)). For copy number alteration
(CNA) analysis of WES data, we used the Copy Number Analysis for
Targeted Resequencing (CONTRA) tool [18] and summarized the
exon-level log2 fold changes of read depth between the normal and
tumor samples into gene-level log2 fold changes. Loss of heterozygosity
(LOH: heterozygous in normal tissue but homozygous in the tumor)
analysis also was performed using WES. We used variant allele fraction
values of normal and tumor samples to determine the LOH region.
Whole Transcriptome Sequencing
The 200- to 500-bp double-stranded cDNA fragments were
purified by agarose gel electrophoresis and amplified using PCR to
produce the library. Raw sequencing reads were produced by Illumina
HiSeq 2000 with 100-bp paired-end reads. After removing noisy raw
reads, which contained the adaptor sequence and more than 10%
unknown bases or low quality bases, the remaining reads were aligned
with the human reference genome (UCSC hg19). To find fusion
transcripts, we utilized three types of fusion discovery software:
deFuse [19], BreakFusion [20], and ChimeraScan [21]. UniGene
clusters were downloaded from the National Center for Biotechno-
logy Information (http://www.ncbi.nlm.nih.gov/) to assist in locating
potential gene fusions. To quantify the gene expression level, thenumber of reads that mapped to the exons of each RefSeq gene was
calculated, and the corresponding reads per kilobase per million reads
(RPKM) [22] value was derived. Possible functional fusions were
annotated using Oncofuse [23] and went through further analysis.
SNP Array
We applied a genome-wide SNP array (Illumina HumanOmni5-
Quad BeadChip, Illumina) using the genomic DNA sample. With B
allele frequency data from GenomeStudio (Illumina) analysis results
for SNP array data, we used the paired parent-specific circular binary
segmentation method for LOH and CNA analysis.
Array Comparative Genomic Hybridization and Identification
of CNAs
Weused the Agilent aCGHG3Human 1×1M array with tumor and
matched normal genomic DNA samples. Raw data were acquired and
normalized using the locally weighted scatterplot smoothing (LOW-
ESS) algorithm using Feature Extraction software ver10.7 (Agilent
software). The significance test for eachCNV region used the Z-statistic
calculated by DNA Analytics ver4.0.81 (Agilent software), which sets
the window size to 1M and Z-score threshold to 4.0.
Use of the Public Database as a Reference
We used gene expression data estimated from WTS to select
possible functional genetic changes in our study. Because R-GBM is a
rare disease and obtaining control samples is not easy, we used a
public database as a reference. First, we compared the RPKM value of
specific genetic changes found in our analysis with normal brain
expression values. Then, we compared the RPKM value of specific
genetic changes found in our analysis with GBM data to determine
whether R-GBM is simply a subtype of GBM. For the normal brain
data, we used the normalized expression dataset from BrainSpan
(http://www.brainspan.org/). For the GBM data, we used datasets
from TCGA (https://tcga-data.nci.nih.gov) and cBioPortal for
Cancer Genomics (http://www.cbioportal.org).
Results
Tumor Purity, Alignment, and Coverage Statistics
The purity of the tumor samples was estimated using SNP array
data with the Allele-specific copy number analysis of tumors
(ASCAT) algorithm [24]. The proportion and the ploidy of tumor
cells in the sample were about 89% and 2.17, respectively (Online
Resource Section 1: Supplementary Figure 1). In WES, the total
numbers of uniquely mapped reads were 181,350,341 and
186,695,100 for normal and tumor samples, respectively. These
data yielded mean target coverages of 210 and 197 for the samples,
respectively (Online Resource Section 2: Supplementary Table 1).
Somatic SNVs and Small Indels Found With WES
We found 46,468 (45,045 in dbSNP138) and 46,191 (44,748 in
dbSNP138) SNVs from the paired normal DNA and tumor DNA,
respectively. A total of 45,542 (44,264 in dbSNP138) SNVs were
commonly observed in both samples. We identified 3753 (3362 in
dbSNP137) and 3678 (3314) small indels from the paired normal
and tumor DNA, respectively. A total of 3594 (3273 in dbSNP138)
small indels were common in both samples (Online Resource Section
3 and 4: Supplementary Figures 2–4). The somatic calling method is
described in the Supplement Text (Online Resource Section 4). As a
result, 38 somatically mutated SNVs and one small indel were
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were found, 13 of which were also found with WTS.
Loss of Function SNVs and Analysis of Small Indels (Online
Resource Section 5)
The candidates for loss of function were selected from the
nonsense, splice junction, and frameshift variants (Supplementary
Table 3 of Online Resource Section 5).
Whole Chromosome Copy Gains and Losses
Gains were identified in chromosomes 3, 7, and 9 from the SNP
array and WES data (Figure 2). Interestingly, chromosome 9 showed
a homozygous deletion of the 9p21 locus that contains the tumor
suppressor genes CDKN2A and CDKN2B (Figure 2B).
CNA Analysis Using WES and Array-CGH
CNA data were generated from array-CGH and WES. First, CNAs
were analyzed with array-CGH with probe-based CNA and inter-
val-based CNA. The probe-based method revealed that more than
80,000 CNA regions were present in tumor tissue compared to paired
normal tissue. The interval-based method revealed 370 tumor-specific
CNA regions. WES analysis identified 323 regions with CNAs, which
included 11 genes that are well-known tumor suppressors and
oncogenes [25,26]: VHL, CTNNB1, PIK3CA, EGFR, CDK6, MET,
EZH2, MLL3, CDKN2A, CDKN2B, and NOTCH1 (Table 2). In
addition, WES, SNP array, and array-CGH analyses showed that
CDKN2A/2B were homozygously deleted. Copy number gain was
observed for CTNNB1, CDK6, VHL, MLL3, EZH2, PIK3CA,
EGFR, NOTCH1, andMET with WES and SNP array analyses.
Fusions Found With WTS
A total of 376 fusions were observed with WTS with deFuse [19],
BreakFusion [20], and ChimeraScan [21]. Interchromosomal fusions
and intrachromosomal fusions N50 kb were selected, and thus, 24
fusions (Online Resource Section 6: Supplementary Table 4) were
analyzed further. Among these 24 fusions, in-frame fusions were
selected for candidate genetic hallmarks in R-GBM.Table 1. List of 23 Candidate Non-Synonymous Somatic SNVs
Chr Position dbSNP Ref Alt Transcript Gene Eff
Chr1 27876290 . G C NM_001029882.2 AHDC1 MI
Chr1 104093621 . C G NM_017619.3 RNPC3 MI
Chr2 30748467 . G A NM_182551.3 LCLAT1 NO
Chr2 209201623 . G A NM_015040.3 PIKFYVE MI
Chr3 52413954 . G A NM_015512.4 DNAH1 MI
Chr3 122247474 . T C NM_031458.2 PARP9 MI
Chr5 50685703 . C G NM_002202.2 ISL1 MI
Chr6 124604235 . G A NM_001040214.1 NKAIN2 MI
Chr7 42962956 . C T NM_002787.4 PSMA2 MI
Chr7 99170311 . A T NM_001083956.1 ZNF655 MI
Chr7 140453136 rs113488022 A T NM_004333.4 BRAF MI
Chr9 14720261 . G A NM_005454.2 CER1 MI
Chr10 100189389 . C G NM_000195.3 HPS1 MI
Chr11 799344 . G A NM_145886.3 PIDD MI
Chr11 124766873 . G A NM_019055.5 ROBO4 MI
Chr12 49237760 . C G NM_004818.2 DDX23 MI
Chr14 21490291 . T A NM_201537.1 NDRG2 MI
Chr18 54424349 . G A NM_015285.2 WDR7 MI
Chr19 6772990 . C T NM_005428.3 VAV1 MI
Chr19 13211542 rs149285767 C T NM_005583.4 LYL1 MI
Chr22 40417337 . C A NM_138435.2 FAM83F MI
ChrX 49840621 . T A NM_001127899.2 CLCN5 MI
ChrX 111698369 . A G NM_001004308.2 ZCCHC16 MI
Chr, Chromosome; Ref, Reference; Alt, Alternative; AA, amino acid; VAF, Variant allele frequency.Selection of Genetic Hallmarks in R-GBM
We used WTS data to investigate functional genetic changes in
R-GBM, and the public database was used as a reference. First, we
compared the RPKM values of specific genetic changes found between
tumor and normal brain tissue (Figure 3).We focused on affected genes
with more than a 4-fold change in expression and integrated the results
among WES, WTS, and array-CGH. Several genes had significant
SNVs, CNAs, or fusions. Among genes with SNVs, NDRG2,
NKAIN2, CER1, and ISL1 were downregulated, whereas PARP9 was
upregulated in the tumor sample of the study patient compared to
normal brain tissue. Among genes with CNAs, NOTCH1, EGFR,
CDK6, EZH2, andMET were upregulated, whereas CDKN2A and 2B
were downregulated in the tumor sample of the study patient compared
to normal brain tissue. These results are summarized in Table 3.
The aforementioned analysis was assumed to have identified
functional genetic changes in the selected genes. In addition, RPKM
values of these selected genes in GBM and R-GBM were compared
(genetic changes inGBMwere obtained from the TCGAdatabase).We
listed genes with more than a 2-fold difference in genetic expression
between conventional GBM and R-GBM. The following significant
alterations between study samples (R-GBM) and conventional GBMs
were found: 1) CER1 and ISL1 had SNVs that were significantly
downregulated. 2) CDKN2A and 2B were genes with CNAs and were
significantly downregulated. 3) NOTCH1, EGFR, CDK6, PIK3CA,
andMETwere genes with CNAs and were significantly upregulated. 4)
PDK1, RASSF8, FKBP15, GALNT6, ITGA6, SLC6A6,
TWIST2,and UPK3BL were significantly up-regulated fusion genes
correlated to R-GBM.Search for GBMs With Similar Genetic Hallmarks in the
TCGA Database
In our case, genetic hallmarks excluding fusions are summarized
below (Table 3): 1) BRAF V600E; 2) NDRG2 I92F and ISL1
C234W mutation; 3) CDKN2A/2B homozygous loss; and 4) EGFR,
CDK6, EZH2, NOTCH1, and MET copy number gain. Subse-
quently, we searched the cBioportal (TCGA provisional data) forect AA Change DepthN DepthT VAFN VAFT RNA-Seq (confirmed)
SSENSE H779Q 81 66 0 0.409 O
SSENSE P474A 169 192 0 0.432 O
NSENSE W42* 266 259 0 0.409 X
SSENSE G1528R 182 174 0 0.379 O
SSENSE E2471K 15 34 0 0.294 O
SSENSE T768A 234 300 0 0.563 O
SSENSE C234W 78 77 0 0.455 X
SSENSE V47I 278 264 0 0.371 X
SSENSE G142R 169 176 0 0.477 O
SSENSE M229L 183 204 0 0.309 O
SSENSE V600E 208 294 0 0.551 O
SSENSE P211S 163 183 0.006 0.874 X
SSENSE S293T 64 63 0 0.397 O
SSENSE S899F 53 67 0 0.373 O
SSENSE R119W 25 23 0 0.478 X
SSENSE D95H 345 269 0 0.353 O
SSENSE I92F 148 148 0 0.338 X
SSENSE G842D 317 318 0.003 0.374 O
SSENSE R58C 154 139 0 0.36 X
SSENSE G119E 283 238 0 0.176 O
SSENSE L275I 283 257 0 0.416 X
SSENSE I196N 165 141 0 0.142 X
SSENSE K138R 298 290 0 0.41 X
Figure 2. Copy number status of R-GBM. (A) Gross copy number changes, (B) variant allele frequency in the tumor sample, and (C) variant
allele frequency in the normal sample.
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used WES data (284 samples), and for gene copy number gain/loss,
we used array-CGH data (497 samples).
Among 284 GBM cases with sequencing data, the BRAF V600E
mutation was found in 1.7% of GBM cases. TheNDRG2mutation was
not found in GBM. However, when we searched for NDRG2 geneticchanges in the array-CGH database,NDRG2was amplified in two cases
(2/497 = 0.4%) and homozygously deleted in three cases (3/497 =
0.6%). For ISL1, no mutation was found in GBM cases. However, the
ISL1 deletion was observed in two GBM cases (2/497 = 0.4%).
Based on array-CGH data from 497 GBM cases, homozygous
deletions of CDKN2A and CDKN2B were found in 62% and 61% of
Table 2. Genes with Copy Number Alterations that Are Well Known to be Associated with Cancer Development and/or Progression
Chr Start End Gene Genetic alteration aCGH WES SNP array Classification Expression Ratio1 * Expression Ratio2 #
Chr3 9022276 9291369 VHL Gain Yes Yes Yes TSG −0.28 3.07
Chr3 41240942 41281939 CTNNB1 Gain Yes Yes Yes Oncogene −0.04 5.83
Chr3 178916609 178922393 PIK3CA Gain Yes Yes Yes Oncogene 1.93 2.92
Chr7 55086951 55214485 EGFR Gain Yes Yes Yes Oncogene 3.02 1.54
Chr7 92234235 92465941 CDK6 Gain Yes Yes Yes Oncogene 3.05 1.86
Chr7 116312459 116438440 MET Gain Yes Yes Yes Oncogene 4.32 3.83
Chr7 148504464 148581441 EZH2 Gain Yes Yes Yes Oncogene 5.29 0.12
Chr7 151832010 152133090 MLL3 Gain Yes Yes Yes Oncogene 0.84 1.94
Chr9 21967751 21994490 CDKN2A Loss Yes Yes Yes TSG −2.38 −1.03
Chr9 22005935 22009013 CDKN2B Loss Yes Yes Yes TSG −3.02 −8.89
Chr9 139388896 139440238 NOTCH1 Gain Yes Yes Yes Oncogene 2.37 2.77
Chr, chromosome; aCGH, array comparative genomic hybridization; WES, whole exome sequencing; Del, deletion; TSG, tumor suppressor gene.
* Expression ratio 1 is the log2 ratio of the expression level (value in RPKM) in our patient over the mean expression level (value in RPKM) in normal brain (http://www.brainspan.org).
# Expression ratio 2 is the log2 ratio of the expression level (value in RPKM) in our patient over the mean expression level (value in RPKM) in glioblastoma multiforme (https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp).
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NOTCH1, and MET were found in 49%, 7%, 4.4%, 0.6%, and
8.9% of the cases, respectively. Interestingly,NOTCH1 copy number
gain, and that of EGFR, CDK6, EZH2, and MET, were mutually
exclusive. Two out of three NOTCH1-amplified cases accompaniedFigure 3. Expression status of selected genetic changes found in
changes with copy number alteration, (B) genetic changes with singl
axis shows the log2 ratio of the expression level (value in RPKM) in ou
brain (http://www.brainspan.org)).the CDKN2A/B homozygous deletion. On the other hand, copy
number gains in EGFR, CDK6, EZH2, and MET were not mutually
exclusive, and co-amplification of these genes was frequently seen.
In three GBM cases with the NDRG2 homozygous deletion, two
had simultaneous homozygous CDKN2A and CDKN2B deletions.the R-GBM sample in comparison with normal brain. (A) genetic
e nucleotide variation, and (C) genetic changes with gene fusion (y
r patient over the mean expression level (value in RPKM) in normal
Table 3. Genetic Hallmarks of Rhabdoid Glioblastoma.
Chr Position Change Gene Amino Acid Change Ratio1 * Ratio2 # Frequency in GBM Other Changes Involving This Gene in GBM
Chr5 50678958 SNV ISL1 C234W −2.62 −6.78 0% Deletion (0.4%)
Chr7 140453136 SNV BRAF V600E 0.50 1.85 1.7% Amplification (4.4%), deletion (0.2%)
Chr14 21490291 SNV NDRG2 I92F −7.16 4.80 0% Amplification (0.4%), deletion (0.6%)
Chr3 178916609 CN gain CDK6 NA 3.05 1.86 7% Mutation (26%)
Chr7 55086725 CN gain EGFR NA 3.02 1.54 49% None
Chr7 116335706 CN gain MET NA 4.32 3.83 8.9% Mutation (0.7%)
Chr7 148504464 CN gain EZH2 NA 5.29 0.12 4.4% Mutation (1.1%)
Chr9 139388896 CN gain NOTCH1 NA 2.37 2.77 0.6% None
Chr9 21968144 CN loss CDKN2A NA −2.38 −1.03 62% Mutation (0.7%)
Chr9 22005935 CN loss CDKN2B NA −3.02 −8.89 61% Mutation (0.4%)
Chr, chromosome; CN, copy number; GBM, glioblastoma multiforme; SNV, single nucleotide variant; NA, not applicable.
* Ratio 1 is the log2 ratio of the expression level (value in RPKM) in our patient over the mean expression level (value in RPKM) in normal brain (http://www.brainspan.org).
# Ratio 2 is the log2 ratio of the expression level (value in RPKM) in our patient over the mean expression level (value in RPKM) in glioblastoma multiforme (https://tcga-data.nci.nih.gov/tcga/tcgaHome2.jsp).
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NKX2-1 homozygous deletion. Regarding gene amplification, one of
the three patients had MET and EZH2 amplifications, and the other
patient harbored EGFR amplification.
Among 198GBM samples with both array-CGH andWES data, only
one sample harbored the BRAF mutation, MET, EGFR, and CDK6
amplifications, and CDKN2A/B homozygous deletion at the same time.
However, no patient harbored the BRAF mutation and NOTCH1
amplification at the same time. The BRAF mutation and EZH2
amplification were also mutually exclusive. To summarize, although our
case of R-GBM is not representative of all R-GBMs, coexistence of the
genetic hallmarks found in our patient is a very rare event in GBM.
Discussion
In this study, we addressed the genomic profile of R-GBM, a very rare
disease entity. At the chromosomal level, we found copy number
gains in chromosomes 3, 7, and 9, and the deletion of 9p21. When
we correlate this karyotypic abnormality with genetic changes, we
made the following observations.
On chromosome 3, PIK3CA was amplified, and its corresponding
expression was elevated compared to normal brain. PIK3CA is
frequently altered in GBM, and indeed, amplification of this gene is
found in 13% of primary GBMs [27]. Hence, the PIK3CA copy
number gain found in our sample was not surprising and implies that
a common genetic denominator exists between GBM and R-GBM.
On chromosome 7, EGFR, EZH2, CDK6, and MET had copy
number gain, and their expression was elevated compared to that in
normal brain tissue. In fact, the gain of chromosome 7 along with
EGFR and MET gene amplification is relatively common in adult
brain tumors including GBM [28]. In addition, EGFR copy number
gain and amplification were observed in a series of R-GBM
cases [9,29]. On the other hand, amplification of EZH2 and CDK6
is not commonly observed; only 4% and 7% of GBM cases had
amplification of these genes, respectively. Moreover, 1.2% of GBM
cases had co-amplification of EZH2 and CDK6, and 0.4% (2 out of
497) of GBM cases also had co-amplification of MET, EZH2, and
CDK6 according to the TCGA database. We reviewed the pathology
slides of these two cases, which are detailed on the websites
(cBioportal case_id=TCGA-06-0187 and cBioportal case ID=
TCGA-19-1390). A pathology review of these two cases did not
provide a definite diagnostic clue regarding R-GBM. Therefore, we
could not draw a definite conclusion regarding whether amplification
of one or more of EZH2, CDK6, or MET may be an irrelevant event
or an oncogenic driver in the pathogenesis of R-GBM.On chromosome 9, NOTCH1 copy number gain and associated
over-expression were observed. Although the role of the Notch
pathway in brain tumors is an area of active investigation, Notch1
signaling is known to promote survival of GBM cells via
EGFR-mediated signaling [30]. In addition, Notch signaling has
oncogenic potential in a model of medulloblastoma [31]. Hence, we
believe that the NOTCH1 copy number gain found in our case may
have substantially contributed to oncogenesis and tumor progression.
However, only three among 497 cases had NOTCH1 amplification
in the TCGA database, which implies that this alteration in
NOTCH1 is not a common event in GBM. Regarding the genomic
profile of these three cases, two harbored the CDKN2A/2B
homozygous deletion as in our case, and one case harbored TP53
and IDH1 missense mutations. As mentioned in the Results section,
NOTCH1 amplification was mutually exclusive with EGFR, MET,
EZH2, and CDK6 amplification in the TCGA database. Hence,
the simultaneous copy number gain in, and over-expression of,
NOTCH1, EGFR, MET, EZH2, and CDK6 in our sample is a very
interesting phenomenon. What is most interesting regarding
NOTCH1 amplification is that one case with NOTCH1 amplifica-
tion in the TCGA database (cBioportal case id=TCGA-02-2483) had
rhabdoid features upon pathology review. Therefore, we believe that
further testing for NOTCH1 copy number gain in other R-GBM
samples is necessary to confirm whether NOTCH1 is a key factor for
rhabdoid morphogenesis.
For chromosome 9, the 9p21 deletion (rather than chromosome 9
copy number gain) was found using WES and SNP microarray. This
alteration was not detectedwith conventional FISH, which confirms the
high sensitivity ofWES and SNP microarray compared to conventional
FISH. Chromosome 9p21 contains CDKN2A and CDKN2B, which
are well-known tumor suppressor genes that play an important role in
GBM. CDKN2A and CDKN2B were homozygously deleted in this
patient, and their expression was correspondingly low. Thus,CDKN2A
and CDKN2B may play an important role in our patient.
As for non-synonymous SNVs excluding BRAF V600E, we
designated the ISL1 and NDRG2 mutations as genetic hallmarks of
R-GBM. We selected these genes for the following reasons. First,
gene expression of ISL1 and NDRG2 was significantly reduced
compared to expression in normal brain, which implies that these
genetic changes are functional. Second, both ISL1 and NDRG2 are
biologically relevant to brain tumor development. ISL1 is required for
neural development, and expression of this gene is associated with
neuroendocrine carcinoma [32,33]. NDRG2 is a well-known tumor
suppressor in brain tumors [34]. In contrast to our sample, ISL1 and
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Instead, homozygous deletion of ISL1 (n = 2) and NDRG2 (n = 3)
was identified in a small subset (0.4% and 0.6%, respectively) of
GBM cases in the TCGA database. As for the NDRG2 deleted cases
(n = 3) in the GBM (TCGA database), KIT, PDGFRA, and CHIC2
amplifications were found in two cases (67%). Amplification of other
oncogenes including MET, EZH2, CDK4, and EGFR was also
identified. Interestingly, for tumor suppressor genes, CDKN2A/2B
homozygous deletion (n = 2) and NKX2-1 homozygous deletion (n =
2) were found in NDRG2-deleted GBMs. NKX2-1 was also
downregulated in our sample and was fused with ARL6IP4
(Supplementary Table 4). Hence, these phenomena observed in the
TCGA database coincide with the genetic changes found in our
sample. More importantly, one case with the NDRG2 deletion in the
TCGA database (cBioportal case_id=TCGA-02-0281) showed
possible GBM with rhabdoid features when we reviewed the
histological images. Hence, we believe that loss of NDRG2 function
may play an important role in R-GBM pathogenesis.
Finally, comparison of genetic changes in our case with those of
ATRT is valuable because ATRT and R-GBM share common
morphologic features. First, genes in the SWItch/Sucrose NonFermen-
table (SWI/SNF) complex, which is a genetic hallmark of ATRT
[12,35,36], were not altered in R-GBM as had previously been shown.
This finding suggests that although ATRT and R-GBM share common
morphologic features, the SWI/SNF complex abnormality is not a key
factor for rhabdoid morphogenesis. However, EZH2 over-expression,
which was recently shown to be important in ATRT [37], was observed
in our sample. EZH2 was both amplified and over-expressed in our
sample. Therefore, EZH2 copy number gain and over-expression may
play an important role in rhabdoid tumor generation.
Here, we addressed genetic hallmarks found in our R-GBM case
including BRAF V600E, ISL1 C234W, NDRG2 I92F, CDKN2A/2B
deletion, NOTCH1 copy number gain, and gain of chromosome 7
(including CDK6, MET, EZH2, and EGFR copy number gain). The
patterns of mutation and gene expression in R-GBM are rather unique
compared to conventional GBM, suggesting that R-GBM is a distinct
disease entity. Among these genetic changes, NOTCH1 copy number
gain andNDRG2mutation, which are rare events in the TCGA GBM
database, appear to be important geneticmarkers in R-GBM formation.
Furthermore, EZH2 copy number gain and over-expression may play
an important role in rhabdoid tumorigenesis.
Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.tranon.2015.05.003.
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